A safety and tolerability study of BIVV020 in adults with cold agglutinin disease

Trial Identifier: PDY16370
Sponsor: Bioverativ, a Sanofi company
Start Date: June 2020
Primary Completion Date: January 2022
Study Completion Date: January 2022
Condition: Anemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Germany Essen, Germany, 45147
Italy, Milano Milano, Italy, 20122
Netherlands Amsterdam, Netherlands, 1105AZ
Norway Bergen, Norway, 5021
United Kingdom, London, City of London, London, City of, United Kingdom, NW1 2PJ
United States, Georgia Fayetteville, Georgia, United States, 30214
United States, Missouri SAINT LOUIS, Missouri, United States, 63110
United States, New York Bronx, New York, United States, 10467
United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15232
United States, Washington Seattle, Washington, United States, 98108